SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

Genmab logo
2 months ago

Director, HCP Marketing, Gyn-Onc

Genmab

Princeton, TX (Hybrid)Full time$206K/yr – $308K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Genmab logo

Director, HCP Marketing, Gyn-Onc

Genmab

Princeton, TX (Hybrid)

$206K/yr - $308K/yrIn-houseFull-timeDirector/executive10+ years exp.
2 months ago
Genmab logo
Genmab

Director, HCP Marketing, Gyn-Onc

Princeton, TX (Hybrid)

$206K/yr – $308K/yrDirector/Executive10+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Lead the gynecologic oncology brand at Genmab, guiding HCP marketing, cross-functional launch readiness, and performance for key accounts.

  • Own brand strategy execution and cross-functional alignment.
  • Must-have: 10+ years oncology marketing and gynecologic oncology launch experience.
  • Standout: Direct team leadership and cross-functional collaboration across clinical, Regulatory, and sales teams.

Job Description

Responsibilities

  • Serve as the brand team expert on current and evolving platforms and opportunities related to HCP, institution, and key accounts in gynecologic oncology
  • Lead a team of HCP marketers
  • Establish and pull through the brand strategy
  • Seamlessly integrate professional promotional strategies into the overall product brand plan
  • Manage detailed tactical plans and develop related content to drive brand goals
  • Collaborate to provide critical input into HCP/Key Acct Institution profiles, targeting and segmentation
  • Partner with Gyn-Onc Consumer Marketing and Digital Marketing to develop and implement cohesive brand campaign, creative, positioning and messaging, etc.
  • Effectively translate primary & secondary data into insight-driven decision making and actionable strategies and tactics
  • Track and provide key performance indicator reports
  • Represent brand during Medical/Legal/Regulatory review meetings to ensure launch readiness

Requirements

  • Bachelor’s degree from an accredited institution is required. Master’s degree is preferred.
  • 10+ years of progressive responsibilities within oncology marketing
  • Brand launch experience is required
  • Launch experience within gynecologic oncology is preferred
  • Ability to travel domestically up to 25%
  • Deep understanding of HCP marketing, Key account strategy, and GPO marketing concepts within pharma/biotech
  • Recent (ADC, IO, targeted therapy, personalized medicine) solid tumor and/or gynecologic oncology launch experience
  • Experience working in the highly complex, dynamic environment of an emerging organization
  • Ability to work cross-functionally and on multiple projects simultaneously
  • Ability to thrive in ambiguity, with an entrepreneurial mind-set and a track record of results

Preferred

  • Launch experience within gynecologic oncology is preferred
  • Startup, emerging pharma, or new team experience desired

Benefits

  • 401(k) Plan: 100% match on the first 6% of contributions
  • Health Benefits: Two medical plan options (including HDHP with HSA), dental, and vision insurance
  • Voluntary Plans: Critical illness, accident, and hospital indemnity insurance
  • Time Off: Paid vacation, sick leave, holidays, and 12 weeks of discretionary paid parental leave
  • Support Resources: Access to child and adult backup care, family support programs, financial wellness tools, and emotional well-being support
  • Additional Perks: Commuter benefits, tuition reimbursement, and a Lifestyle Spending Account for wellness and personal expenses
Genmab logo

Genmab

4.4 Glassdoor

We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer

Founded in 1999
Valby, Capital Region of Denmark, DNK
2.7K employees (107 in marketing)
www.genmab.com
92% recommend to a friend
98% CEO approval

Traffic Signals

Monthly Visitors
114.3K
Monthly Google Ads Budget
$4.1K
Traffic Source Mix
Search
46.3%
Direct
38.3%
Referral
8.6%
Social
4.9%
Paid
1.7%

Headcount Trend

Current headcount: ~2.7K

Marketing Team

Marketing Team Size
102 (4% of company)
Median Career Experience
19.5 years
Median Tenure
4.6 years

People

Marketing Leadership

Geoffrey Gordon
Geoffrey Gordon
Vice President, US Marketing, Hematology
At the company for 5 years 2 months
Javier Pintado
Javier Pintado
Vice President, Global Marketing
At the company for 9 years
Mark Blazejewski
Mark Blazejewski
Head, Market Access Strategy and Marketing
At the company for 1 year 7 months
Nate Ross
Nate Ross
Head, US Marketing, Gyn Onc
At the company for 6 years 1 month

Funding

Total Funding
$11.7B
Last Raise
$6B
Post IPO Debt, 4 months ago

Funding History

  • Nov 2025
    Post IPO Debt • $6B
  • Sep 2025
    Post IPO Debt • $5.5B
  • Jul 2010
    Post IPO Equity • $134M

Recent News

M&A analysis: Genmab bucks the bargain basement trend
Oct 6, 2025 • Oncology Pipeline
Foley Hoag Provides IP Due Diligence Counsel to Genmab A/S on Acquisition of Merus N.V.
Oct 1, 2025 • Foley Hoag
Genmab to Acquire Merus and Novel Advanced Cancer Prospect for $8 Billion
Oct 1, 2025 • Inside Precision Medicine
Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab
Sep 30, 2025 • Latham & Watkins LLP
Genmab to Acquire Merus for $8B, Expanding Bispecific Antibody Cancer Pipeline
Sep 30, 2025 • Genetic Engineering and Biotechnology News
Genmab to acquire Merus in $8B biotech deal
Sep 30, 2025 • NJBIZ
Why Genmab Stock Was Marching Higher Today
Sep 30, 2025 • The Motley Fool
Genmab to acquire Merus shares for $8bn
Sep 30, 2025 • Pharmaceutical Technology
Genmab to buy Merus in $8B deal
Sep 29, 2025 • statnews.com
A&O Shearman advises Genmab on its proposed USD8 billion acquisition of Merus
Sep 29, 2025 • A&O Shearman
Genmab pays $8B to buy Merus and its phase 3 bispecific that wowed analysts
Sep 29, 2025 • Fierce Biotech
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
Sep 29, 2025 • Investor's Business Daily
Genmab to Buy Cancer-Treatment Developer Merus For $8 Billion in Cash
Sep 29, 2025 • The Wall Street Journal
Genmab to acquire closely watched cancer drug in $8B Merus buyout
Sep 29, 2025 • BioPharma Dive
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Sep 29, 2025 • GlobeNewswire
Genmab Agrees to Acquire Merus for $8 Billion
Sep 29, 2025 • MarketScreener
Genmab Buys Rising Cancer Star Merus for $8B
Sep 29, 2025 • BioSpace
Genmab in Advanced Talks to Buy Dutch Drugmaker Merus
Sep 29, 2025 • MarketScreener
Danish biotech firm Genmab to acquire Dutch oncology company Merus for €6.8B
Sep 29, 2025 • Silicon Canals
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, HFWA, TIPT on Behalf of Shareholders
Sep 29, 2025 • PR Newswire
Trending tickers: Alibaba, AstraZeneca, GSK, Stellantis and Genmab
Sep 29, 2025 • Yahoo Finance - Business Finance, Stock Market, Quotes, News
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
Sep 29, 2025 • Yahoo Finance
Confirmed: Genmab Acquires Cancer Drug Company Merus
Sep 29, 2025 • MarketScreener
U.S. Futures, European Stocks Up
Sep 29, 2025 • Morningstar.com
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
Sep 28, 2025 • Reuters
Genmab to acquire for $8B in cash (update) (GMAB:NASDAQ)
Sep 28, 2025 • Seeking Alpha
Genmab Nears Deal to Buy Cancer Drugmaker Merus
Sep 28, 2025 • Bloomberg.com
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Sep 25, 2025 • Genmab A/S
Crossroads4Hope to Host Inspiring Hope Gala October 8, 2025
Sep 25, 2025 • PRLog
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Sep 24, 2025 • Morningstar.com
Novartis Announces New Data from Two Kesimpta®? Studies in Relapsing Multiple Sclerosis
Sep 24, 2025 • MarketScreener
Novartis' Kesimpta achieves new positive results in multiple sclerosis
Sep 24, 2025 • MarketScreener
Major Shareholder Announcement
Sep 24, 2025 • PharmiWeb
Major Shareholder Announcement
Sep 23, 2025 • Genmab A/S
Genmab upgraded to Buy at Guggenheim on royalty revenue upside potential
Sep 23, 2025 • thefly.com
Guggenheim gets more bullish on Genmab, upgrades shares
Sep 23, 2025 • thefly.com
Genmab says Orbis holds 5.03% of share capital
Sep 23, 2025 • thefly.com
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
Sep 19, 2025 • MarketScreener
TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
Sep 19, 2025 • PR Newswire
Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)
Sep 17, 2025 • Yahoo Finance
In the clinic for Sept. 17, 2025
Sep 17, 2025 • BioWorld Financial Watch
Genmab drops ProfoundBio-derived ADC as it refocuses oncology portfolio
Sep 17, 2025 • Pharma Letter
Genmab discards clinical ADC picked up in last year's $1.8B ProfoundBio buy
Sep 16, 2025 • Fierce Biotech
Genmab takes its Profound buy into endometrial | ApexOnco - Clinical Trials news and analysis
Sep 16, 2025 • Oncology Pipeline
Antibody Production Market Outlook 2025–2035 | CAGR 11.2% & Market Trends
Sep 15, 2025 • EIN Presswire
Genmab: A Matter Of Time (NASDAQ:GMAB)
Sep 12, 2025 • Seeking Alpha
Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S
Sep 11, 2025 • Yahoo Finance
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
Sep 11, 2025 • Scancell Holdings Plc
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
Sep 11, 2025 • BioSpace
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
Sep 10, 2025 • Morningstar.com
Transactions with shares and linked securities in Genmab
Sep 9, 2025 • GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Sep 9, 2025 • Genmab A/S
Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed?
Sep 6, 2025 • Yahoo Finance
AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial
Sep 4, 2025 • Clinical Trials Arena
AbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient setting
Sep 3, 2025 • Seeking Alpha
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Sep 3, 2025 • GlobeNewswire
Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally
Aug 29, 2025 • Yahoo Finance
Breakthrough designation for Genmab’s Rina-S in USA
Aug 27, 2025 • Pharma Letter
Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight
Aug 27, 2025 • PR Newswire
Genmab Receives FDA Breakthrough Therapy Designation for
Aug 26, 2025 • GlobeNewswire
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
Aug 26, 2025 • PharmiWeb
Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
Aug 26, 2025 • thefly.com
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 26, 2025 • Genmab A/S
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
Aug 26, 2025 • Business Wire
Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
Aug 13, 2025 • PharmaTimes
European shares near two-week highs on Fed rate cut expectations
Aug 13, 2025 • Investing.com
Global markets hover close to record highs as bullish sentiment hits Wall Street
Aug 13, 2025 • Irish Times
William Blair Remains Bullish on Genmab A/S (GMAB)
Aug 12, 2025 • Yahoo Finance
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Aug 12, 2025 • Genmab A/S
Genmab Earnings: Robust Demand for Darzalex Drives Growth; Shares Very Undervalued
Aug 11, 2025 • Morningstar Canada
In the clinic for Aug. 11, 2025
Aug 11, 2025 • BioWorld Financial Watch
Genmab’s Epkinly Shows Major Survival Benefit in Relapsed, Refractory Follicular Lymphoma
Aug 8, 2025 • Applied Clinical Trials
Trial results set up AbbVie, Genmab's Epkinly for key expansion in follicular lymphoma
Aug 8, 2025 • Fierce Pharma
Genmab AS (GMAB) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Advancements
Aug 8, 2025 • Yahoo Finance
Genmab Updates Revenue, Operating Profit Outlook for FY25
Aug 8, 2025 • MarketScreener
Genmab eyes US nod after epcoritamab combo clears Phase III hurdle
Aug 8, 2025 • Pharma Letter
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
Aug 8, 2025 • PharmiWeb
Genmab lifts Q2 revenue on royalties, raises full-year outlook
Aug 8, 2025 • Pharma Letter
Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met
Aug 7, 2025 • GlobeNewswire
AbbVie, Genmab eye second-line FL slot for Epkinly after Phase III win
Aug 7, 2025 • FirstWord Pharma
Genmab stock rises on trial win, guidance raise (GMAB:NASDAQ)
Aug 7, 2025 • Seeking Alpha
Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More
Jul 29, 2025 • Research and Markets
TD Cowen Maintains a Hold on Genmab A/S (GMAB)
Jul 28, 2025 • Yahoo Finance
Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight
Jul 28, 2025 • PR Newswire
Transcript : Genmab A/S - Special Call
Jul 25, 2025 • MarketScreener
Truist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook
Jul 24, 2025 • Yahoo Finance
iOnctura Appoints Dr. Neil Gallagher and Anthony Mancini To Board
Jul 24, 2025 • citybiz
Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL
Jul 24, 2025 • Research and Markets
iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
Jul 24, 2025 • PR Newswire UK
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
Jul 23, 2025 • PharmiWeb
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Jul 22, 2025 • Yahoo Finance
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
Jul 16, 2025 • BioSpace
Genmab reports Q2 worldwide net sales of Darzalex $3.54B
Jul 16, 2025 • thefly.com
Chutes & Ladders—Pfizer’s longtime reputation wrangler plans departure
Jul 11, 2025 • FierceBiotech
Genmab (GMAB) Announced Results From its EPCORE NHL-2 Trial
Jul 10, 2025 • Yahoo Finance
Genmab stops a mystery project | ApexOnco - Clinical Trials news and analysis
Jul 9, 2025 • Oncology Pipeline
Genmab grows workforce, expands NJ campus
Jul 2, 2025 • NJBIZ
Appointments and advancements for July 2, 2025
Jul 2, 2025 • BioWorld Financial Watch
Genmab expands U.S. footprint with Plainsboro facility
Jul 1, 2025 • ROI-NJ
Genmab Announces Changes to its Executive Committee
Jul 1, 2025 • Yahoo Finance